-- Andrew T. Kaplan, 10% Owner, Director, on April 16, 2026, executed a purchase for 8,398,438 shares in Kailera Therapeutics (KLRA) for $134,375,008. Following the Form 4 filing with the SEC, Kaplan has control over a total of 26,255,581 common shares of the company, with 26,255,581 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/2096997/000119312526164388/xslF345X05/ownership.xml